Executive summary

This study retrospectively reviewed 53 patients who received salvage PBT for locoregionally recurrent NSCLC. With a median follow-up time of 15.0 months, 26 patients (49.1%) experienced disease progression, and the 2-year OS, LC, and PFS rate were 79.2%, 68.2%, and 37.1%, respectively. Grade 3 toxicities occurred in 8 patients (15.1%): esophagitis in 2, dermatitis in 3, and pulmonary toxicities in 4. 

Key content topics
Top cancer treatments